Epidemiologic analysis and control strategy of *Klebsiella pneumoniae* infection in intensive care units in a teaching hospital of People’s Republic of China

Chunrui Wang1
Zhe Yuan1
Wenxiang Huang1
Li Yan2
Jun Tang3
Cheng-wei Liu3

1Department of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, People’s Republic of China; 2Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, People’s Republic of China; 3Department of Infectious Diseases, Key Laboratory of Infectious and Parasitic Diseases in Chongqing, Chongqing 400016, People’s Republic of China

**Background:** *Klebsiella pneumoniae* (KP) is the most common pathogen isolated in intensive care units (ICUs) and the most frequently encountered carbapenemase-producing Enterobacteriaceae. Increasing antimicrobial drug resistance, especially in carbapenem-resistant KP (CRKP), can limit the choice of antibiotics used for the treatment of infectious diseases and further poses a negative impact on patient outcome. However, the reason behind this increasing resistance is not well known.

**Patients and methods:** A retrospective analysis of laboratory records and clinical cases of KP infection in the ICUs of a hospital from January 2013 to December 2017 was conducted. The disk diffusion method and double-paper synergy test were used to test drug sensitivity for extended-spectrum β-lactamase (ESBL) detection. WHONET5.6 and SPSS 21.0 software were used for statistical analysis.

**Results:** A total of 64.8% (570/847) of patients with KP infection were older than 60 years. The lower respiratory tract was the main infection site, accounting for 70.84% (600/847); the highest rate of ICU admission was for neurosurgery, accounting for 28.69% (243/847). Some 444 multidrug-resistant KP strains were detected, including 69 CRKP and 299 ESBL-producing strains. In the past 5 years, the resistance rate of detected strains to common antibiotics increased 444 multidrug-resistant KP infection in the ICUs of a hospital from January 2013 to December 2017 was conducted.

**Conclusions:** CRKP and ESBL KP prevalence and resistance rates gradually increased in our ICUs in the past 5 years. The reasons for this are manifold. Regular surveillance of resistance, rational use of antibiotics, and other effective infection control measures need to be strengthened to slow down the production of multidrug-resistant bacteria and prevent their spread in ICU settings.

**Keywords:** *Klebsiella pneumoniae*, antibiotic resistance, carbapenem resistance, intensive care units

**Introduction**

In recent years, *Klebsiella* spp. have been among the most common pathogens isolated in intensive care units (ICUs), and *Klebsiella pneumoniae* (KP) is the most frequently encountered carbapenemase-producing Enterobacteriaceae (CRE).1 The US Centers for Disease Control and Prevention (CDC) bacterial resistance threat report has classified it as having a serious drug resistance level. KP belongs to the Enterobacteriaceae

Correspondence: Zhe Yuan
Department of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, People’s Republic of China
Tel +86 23 8901 2513
Fax +86 23 8901 2513
Email yuanzhe-1030@163.com

This article was published in the following Dove Medical Press journal: Infection and Drug Resistance
**Klebsiella**, a facultative anaerobic bacterium that is a common pathogen in hospitals. Under the selective pressure generated by the application of broad-spectrum antibacterial drugs, multidrug-resistant KP (MDRKP) strains, including carbapenem-resistant KP (CRKP) and extended-spectrum \( \beta \)-lactamase KP (ESBLKP), strains are increasing, which accounts for substantial increases in illness and death. Few antimicrobial therapy options exist for infections caused by CRKP.

ICUs have been described as a factory for creating, disseminating, and amplifying antimicrobial resistance due to their extremely vulnerable population of critically ill patients, heavy use of invasive procedures, and the frequent application of antimicrobials. ICU stay itself is an independent risk factor for CRKP infection. KP resistance has become a serious problem of clinical concern. As a consequence, epidemiologic and drug resistance analysis of ICU KP is important for controlling nosocomial infections and facilitating the choice and the efficacy of empirical therapy. Additionally, this knowledge is important for the design and the implementation of interventions aiming to prevent the spread of antimicrobial resistance. This study focused on two main points. First, it describes the epidemiological characteristics and drug resistance of KP infection in patients in an ICU setting. Second, it discusses the reasons behind this resistance, including the high extended-spectrum \( \beta \)-lactamase (ESBL) rate and increased CRKP detection.

**Patients and methods**

**Study design and population**

We retrospectively analyzed laboratory records and clinical cases from January 2013 to December 2017 in the First Affiliated Hospital of Chongqing Medical University, a tertiary university hospital with 3,200 beds in Chongqing, southwest China. Looking up at all KP isolates in ICUs in the hospital in 5 years, and excluding the same isolate from the same patient, patients with the first isolate that was defined as causing infection were included in this study. When two or more kinds of bacteria were cultured in the infected site, the KP infection strain was selected, excluding patients with other concomitant infections. Epidemiological characteristics and drug resistance and treatment outcomes were retrieved from the medical records by two experienced medical doctors. The information about the patient demographics (age, gender), comorbidities (diabetes mellitus, hypertension, coronary atherosclerotic heart disease, cerebrovascular accident, renal failure, heart failure, malignant tumor), and source of infection was collected. Additionally, the general state of patients during KP infection was assessed, such as septic shock and multiple organ dysfunction.

**Bacterial identification and drug sensitivity test**

Bacterial cultures were processed in the clinical microbiology laboratory. Isolates were identified using the VITEK 2 Compact system or the VITEK MS system (bioMérieux, Lyon, France), and antimicrobial susceptibilities were determined in vitro using a VITEK 2 Compact AST-GN13 card (bioMérieux). The carbapenem-resistant isolates were confirmed manually by the standard broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) guidelines. The CLSI 2014 standard judges resistance, intermediate, and sensitivity. *Escherichia coli* American Type Culture Collection 25922 was used as a quality control strain during the antimicrobial susceptibility testing. Additionally, VITEK 2 compact AST-GN13 cards were used to test the antibiotic susceptibilities of all isolates to ampicillin, cephalaxide, ceftriaxone, cefepime, cefotaxim, cefotetan, ampicillin–sulbactam, piperacillin–tazobactam, cefoperazone–sulbactam, ertapenem, imipenem, meropenem, amikacin, gentamicin, ciprofloxacin, minocycline, and tigecycline. ESBL production was measured by the double-disc synergy test and the disk diffusion method performed on Mueller–Hinton agar supplemented with cefoxitin (250 mg/L).

**MDRKP, pan-resistant KP, and CRKP**

A strain was judged to be MDRKP if it was nonsusceptible to \( \geq 1 \) agent in \( \geq 3 \) antimicrobial categories (including third-generation cephalosporin, aminoglycoside, fluoroquinolone, \( \beta \)-lactamase inhibitors, carbapenems, cephemycins, glycolcyclines, phosphonic acids, polymyxins, and tetracyclines). Extensively drug-resistant strain was nonsusceptible to \( \geq 1 \) agent in all, but \( \leq 2 \) categories. Pandrug-resistant strains were nonsusceptible to all antimicrobial agents listed. CRKP strains were resistant to at least one of the carbapenems, including imipenem, meropenem, and ertapenem.

**Data collection and definition**

**Inclusion criteria**

Positive pathogen culture in sterile sites such as cerebrospinal fluid, bile, bloodstream, and marrow was considered to show an infectious pathogen. If pathogens were cultivated from a nonsterile site, we distinguished between colonization and infection by estimating the patient’s clinical infection symptoms, and laboratory examination including white blood cell count (WBC), neutrophil percentage (NEU), procalcitonin.
(PCT), C-reactive protein (CRP), imaging basis (X-ray, computed tomography (CT) ultrasound examination), qualified specimen (sputum culture ≥10^5 cfu/ml; bronchoalveolar lavage fluid culture ≥10^6 cfu/ml; urine culture count ≥10^6 cells/ml), urine culture count ≥10^5 cells/mL). In addition, the proper time point and site were relative to positive KP culture (retaining specimens before using antibiotics, collecting the first sputum from the deep part of the lung in the early morning, keeping clean middle urine, blood culture in patients with chills).

**Definition of infection**

Pneumonia: the fifth point plus one of the items 1) cough with purulent sputum; 2) temperature ≥37.3°C; 3) pulmonary physical signs or moist rales; 4) WBC >10×10^9/L; 5) chest X-ray or chest CT changes. Acute pyelonephritis: fever or backache, with WBC ≥10×10^12/L or CRP ≥10 mg/L, accompanied by one of the following urine test indicators: 1) urine routine: WBC ≥5/high-power field (HP), erythrocytes >3/HP, or clean middle urine WBC >10/HP; 2) urine culture count ≥10^5 cells/mL), in addition, the proper time and site were relative to positive KP culture (retaining specimens before using antibiotics, collecting the first sputum from the deep part of the lung in the early morning, keeping clean middle urine, blood culture in patients with chills).

**Statistical analysis**

Statistical analyses were conducted with the statistical package SPSS for Windows, version 22.0 (IBM Corporation, Armonk, NY, USA). The results are listed as the mean (±SD) and median (first–third quartile) for continuous variables with normal and skewed distributions, respectively. Continuous variables were compared using Student’s unpaired t-test or the Mann–Whitney U test. Categorical variables were compared by Pearson's chi-squared test or Fisher’s exact test, as appropriate. Associations were given as ORs with a 95% CI. In all analyses, P<0.05 was considered significant.

**Ethics**

The study was approved by the Chongqing Medical University Institutional Review Board and Biomedical Ethics Committee. All patient data were analyzed in anonymity. This retrospective study did not directly interfere with any patient or show the patient’s name, medical record number, or other personal information. Moreover, there was no adverse effect on the rights of patients; therefore, the ethics committee waived the need for written informed consent provided by participants.

**Results**

**Strain characteristics and detection rate**

According to the inclusion criteria, 847 infected isolates of KP were diagnosed in 2013–2017, including 539 males and 308 females, with an average age of (68±14) years, and those ≥60 years old accounted for 67.30% (570/847). A total of 90% of patients had invasive procedures such as deep vein catheterization, tracheal intubation, gastrointestinal decompression, and long-term application of generally broad-spectrum antibiotics. A total of 847 infected strains were diagnosed. MDRKP strains accounted for 52.42% (444/847), of which ESBL strains were 36.36% (299/847). The detection rates of ESBL strains in 2013–2017 were 33.33% (63/189), 32.67% (49/150), 37.43% (64/171), 33.95% (55/162), and 38.86% (68/175), respectively. CRKP strains accounted for 8.15% (69/847), and the detection rates from 2013 to 2017 were 4.76 (9/189), 4.67% (7/150), 2.92% (5/171), 12.35% (20/162), and 16.00% (28/175), respectively. The difference was statistically significant (P<0.005), as shown in Table 1.
Wang et al

In the 847 strains, the sputum distribution rate was the highest at 68.94% (584/847), followed by urine at 15.11% (128/847) and blood at 8.03% (68/847). Five ICUs with 110 beds in our hospital were included in this article, of which comprehensive ICU had 30 beds. The Neurology, Neurosurgery, Thoracic surgery, and Respiratory Medicine ICUs had 20 beds each. The Neurosurgical ICU had the highest proportion at 28.69% (243/847), followed by the Neurology ICU at 26.92% (228/847) and the Respiratory Medicine ICU at 18.89% (160/847).

### Table 1. Demographic and clinical characteristics of patients with KP infection in ICU in 2013–2017, n (%)

| Clinical characteristics | Non-ESBLs/CRKP (n=479) | ESBKLP (n=299) | CRKP (n=69) | KP (N=847) |
|--------------------------|--------------------------|----------------|-------------|-------------|
| Length of stay (days)    | 18.3±16.5                | 28.7±24.1      | 34.2±26.5   | 26.2±22.6   |
| Age (years) ≥60          | 319 (66.60%)             | 197 (65.88%)   | 54 (78.26%) | 570 (64.80%)|
| Male gender              | 286 (59.71%)             | 203 (67.89%)   | 50 (72.46%) | 539 (63.63%)|
| Chronic diseases          |                          |                |             |             |
| Diabetes                 | 214 (44.68%)             | 137 (45.82%)   | 30 (43.47%) | 381 (44.98%)|
| Hypertension             | 96 (20.04%)              | 210 (70.23%)   | 24 (34.78%) | 330 (38.96%)|
| CHD                      | 63 (13.15%)              | 53 (17.73%)    | 19 (27.54%) | 135 (15.94%)|
| Cerebrovascular accident | 15 (3.13%)               | 126 (42.14%)   | 15 (21.74%) | 156 (18.42%)|
| Renal failure            | 15 (3.13%)               | 53 (17.73%)    | 13 (18.84%) | 81 (9.56%)  |
| Heart failure            | 48 (10.02%)              | 62 (20.74%)    | 17 (24.64%) | 127 (14.99%)|
| Malignant tumor          | 82 (17.12%)              | 48 (16.05%)    | 8 (11.59%)  | 138 (16.29%)|
| Clinical symptoms        |                          |                |             |             |
| Fever                    | 479 (100.00%)            | 299 (100.00%)  | 69 (100.00%)| 847 (100.00%)|
| WBC ≥4.0×10⁹/L           | 440 (91.86%)             | 245 (81.94%)   | 60 (86.95%) | 745 (87.95%)|
| NEU >75%                 | 409 (85.39%)             | 244 (81.60%)   | 58 (84.06%) | 711 (83.94%)|
| PCT >4.0×10⁹/L           | 464 (96.87%)             | 283 (94.65%)   | 64 (92.75%) | 811 (95.75%)|
| CRP >10 mg/L             | 479 (100.00%)            | 299 (100.00%)  | 69 (100.00%)| 847 (100.00%)|
| Outcome                  |                          |                |             |             |
| Septic shock             | 177 (36.95%)             | 182 (60.87%)   | 52 (75.36%) | 411 (48.52%)|
| MOD                      | 132 (27.56%)             | 143 (47.83%)   | 46 (66.67%) | 321 (37.89%)|
| Source of infection      |                          |                |             |             |
| Pneumonia                | 317 (66.18%)             | 215 (71.90%)   | 52 (75.36%) | 584 (68.94%)|
| Acute pyelonephritis     | 88 (18.37%)              | 28 (9.36%)     | 12 (17.40%) | 128 (15.11%)|
| bloodstream infection     | 45 (9.39%)               | 17 (5.69%)     | 6 (8.70%)   | 68 (8.03%)  |
| Central venous catheter related | 12 (2.51%) | 28 (9.36%) | 8 (11.60%) | 48 (5.67%)  |
| Incision infection       | 17 (3.55%)               | 15 (5.02%)     | 5 (7.25%)   | 37 (4.37%)  |
| Specimen type            |                          |                |             |             |
| Sputum                   | 328 (68.48%)             | 210 (70.23%)   | 46 (66.67%) | 584 (70.84%)|
| Urine                    | 73 (15.24)               | 45 (15.05)     | 10 (14.49)  | 128 (6.26)  |
| Bloodstream              | 34 (5.0)                 | 28 (9.36)      | 6 (8.69)    | 68 (5.79)   |
| Bronchoalveolar lavage fluids | 16 (3.34) | 11 (3.67) | 3 (4.34) | 30 (3.54)   |
| Sterile site*            | 16 (3.34)                | 10 (3.34)      | 2 (2.89)    | 28 (3.30)   |

Note: Sterile site included cerebrospinal fluid and bile.

Abbreviations: CHD, coronary atherosclerotic heart disease; CRKP, carbapenem-resistant KP; CRP, C-reactive protein; ESBL, extended-spectrum β-lactamase; ICU, intensive care unit; KP, Klebsiella pneumoniae; MOD, multiple organ dysfunction; NEU, neutrophil percentage; PCT, procalcitonin; WBC, white blood cell count.

**Strain source and distribution in various departments**

In the 847 strains, the sputum distribution rate was the highest at 68.94% (584/847), followed by urine at 15.11% (128/847) and blood at 8.03% (68/847). Five ICUs with 110 beds in our hospital were included in this article, of which comprehensive ICU had 30 beds. The Neurology, Neurosurgery, Thoracic surgery, and Respiratory Medicine ICUs had 20 beds each. The Neurosurgical ICU had the highest proportion at 28.69% (243/847), followed by the Neurology ICU at 26.92% (228/847) and the Respiratory Medicine ICU at 18.89% (160/847).

**Drug resistance analysis of KP to common antibiotics**

As shown in Table 2, all isolates were resistant to ampicillin, and no isolates were resistant to tigecycline. The resistance rate to ceftriaxone, ampicillin/sulbactams, aminoglycosides, ciprofloxacin, and minocycline was relatively stable and to other antibiotics increased to different degrees. Among β-lactam drugs, the proportion of isolates that were resistant to ceftriaxone or ampicillin/sulbactams was high: 44.4% or 40.5% of the isolates showed no sensitivity to ceftriaxone or ampicillin/sulbactams, respectively. Low resistance rates to cefotetan,
carbapenem antibiotics, and piperacillin/tazobactam were found (7.0%, 10.4%, and 10.3%, respectively). For aminoglycosides, the resistance rate to gentamicin (31.3%) was higher than that to amikacin (10.9%). Some 24.3% and 30.5% of the isolates were resistant to ciprofloxacin and minocycline, respectively.

**ESBL-producing KP resistance to common antibiotics**

As shown in Table 3, almost all ESBL strains were resistant to ampicillin and no isolates were resistant to tigecycline.

### Table 2

| Antimicrobial agent     | 2013 (n=189) | 2014 (n=150) | 2015 (n=171) | 2016 (n=162) | 2017 (n=175) | 2013–2017 (N=847) |
|-------------------------|--------------|--------------|--------------|--------------|--------------|-------------------|
| Ampicillin              | 100.0        | 100.0        | 100.0        | 100.0        | 100.0        | 100.0             |
| Ceftazidime             | 25.9         | 26.0         | 29.2         | 30.6         | 28.6         | 28.1              |
| Ceftriaxone             | 41.3         | 40.7         | 41.5         | 47.8         | 50.6         | 44.4              |
| Cefepime                | 14.1         | 14.0         | 19.6         | 25.7         | 32.3         | 21.2              |
| Cefoxitin               | 14.4         | 15.2         | 16.5         | 24.7         | 33.7         | 25.1              |
| Cefotetan               | 2.7          | 2.7          | 2.4          | 12.4         | 14.9         | 7.0               |
| Amoxicillin–sulbactam   | 50.3         | 50.7         | 46.8         | 53.4         | 52.0         | 40.5              |
| Piperacillin–tazobactam | 4.8          | 6.0          | 6.6          | 16.8         | 18.1         | 10.4              |
| Cefoperazone–sulbactam  | 3.1          | 6.6          | 9.2          | 18.8         | 20.7         | 15.4              |
| Ertapenem               | 5.4          | 4.8          | 3.0          | 12.6         | 16.2         | 8.4               |
| Imipenem                | 2.1          | 2.7          | 2.9          | 11.8         | 16.0         | 7.1               |
| Meropenem               | 0.0          | 0.0          | 3.1          | 11.9         | 16.2         | 10.3              |
| Amikacin                | 12.3         | 11.5         | 4.9          | 13.6         | 12.6         | 10.9              |
| Gentamicin              | 30.2         | 28.0         | 26.9         | 36.7         | 34.9         | 31.3              |
| Ciprofloxacin           | 25.4         | 26.7         | 23.4         | 24.8         | 21.7         | 24.3              |
| Minocycline             | 27.0         | 26.6         | 33.1         | 28.5         | 30.0         | 30.5              |
| Tigecycline             | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0               |

### Table 3

| Antimicrobial agent     | 2013 (n=63) | 2014 (n=49) | 2015 (n=64) | 2016 (n=55) | 2017 (n=68) | 2013–2017 (n=299) |
|-------------------------|-------------|-------------|-------------|-------------|-------------|-------------------|
| Ceftazidime             | 50.8        | 55.1        | 59.7        | 65          | 74          | 61                |
| Ceftriaxone             | 96.8        | 95.9        | 100         | 98.2        | 98.5        | 98                |
| Cefepime                | 46          | 48.1        | 56.2        | 60          | 64.7        | 53.1              |
| Cefoxitin               | 15.7        | 16.8        | 21          | 18.9        | 19.7        | 19.9              |
| Cefotetan               | 1.6         | 2           | 0           | 0           | 0           | 0.7               |
| Amoxicillin–sulbactam   | 95.2        | 93.9        | 96.9        | 90.9        | 94.1        | 94.3              |
| Piperacillin–tazobactam | 7.9         | 8.2         | 11.1        | 12.7        | 14.7        | 11.1              |
| Cefoperazone–sulbactam  | 0           | 0           | 14.5        | 20.4        | 22.7        | 18.6              |
| Ertapenem               | 0           | 0           | 0           | 0           | 0           | 0                 |
| Imipenem                | 0           | 0           | 0           | 0           | 0           | 0                 |
| Meropenem               | 0           | 0           | 0           | 0           | 0           | 0                 |
| Amikacin                | 23.3        | 21.3        | 11.1        | 5.8         | 11.7        | 14.5              |
| Gentamicin              | 52.4        | 51          | 62.5        | 61.8        | 58.8        | 57.5              |
| Ciprofloxacin           | 47.6        | 46.9        | 48.4        | 29          | 30.9        | 40.5              |
| Minocycline             | 55.9        | 55          | 56.5        | 56.6        | 56.9        | 56.7              |
| Tigecycline             | 0           | 0           | 0           | 0           | 0           | 0                 |

*Abbreviation: ESBL, extended-spectrum β-lactamase.*
and 14.5%, respectively); 40.5% and 56.7% of the isolates were resistant to ciprofloxacin and minocycline, respectively.

**CRKP resistance to common antimicrobial drugs**

In the past 5 years, 69 CRKP strains and 47 pan-resistant strains were isolated in our ICUs. All isolates were resistant to β-lactam antibiotics, and no isolates were resistant to tigecycline. The resistance rates were 55.6%, 42.9%, 9%, 90%, and 85.7% for amikacin; 77.8%, 85.7%, 20.0%, 90.0%, and 89.3% for gentamicin; 88.9%, 100.0%, 80.0%, 90.0%, and 89.3% for ciprofloxacin; and 22.2%, 14.3%, 60.0%, 15.0%, and 21.4% for minocycline in 2013, 2014, 2015, 2016, and 2017, respectively.

**Discussion**

To our knowledge, this is the first study in southwest of People’s Republic of China to evaluate the clinical characteristics and evolution of antibiotic resistance of CRKP infection in an ICU setting. In this study, we assessed the epidemiology characteristics of KP infection in our ICUs. Our analysis revealed that elderly patients over 60 years old were susceptible to KP infection in the ICU, and most of them had invasive devices and long-term application of generally broad-spectrum antibiotics. Reported risk factors for infection with ESBL are prior use of antimicrobials, ICU stay, indwelling devices, increased illness severity, prolonged hospitalization, emergency intra-abdominal surgery, mechanical ventilation, and residence in nursing homes.

Our research shows that patients with coma or poor consciousness or without spontaneous respiration were under high risk of infection.

ESBLKP has become a critical issue worldwide, and Asia is no exception. In People’s Republic of China, the ESBL-positive rate in KP was between 37.6% and 30.1% from 2011 to 2014. In this research, we found ESBL-positive strain detection rates that ranged from 33.33% in 2013 to 38.86% in 2017. Approximately 61% of ESBLKP strains were resistant to cefazidime, and >95% were resistant to ceftriaxone, which could be related to the ESBL genotype and use of antibiotics in our hospital. In the past 10 years, CTX-M, especially CTX-M-3 and CTX-M-14 types, accounted for >70% of all genotypes in People’s Republic of China, which has high hydrolysis activity to cefotaxime but weak hydrolysis ability to ceftazidime. In addition, the third-generation cephalosporins used in North America are mainly ceftazidime, while ceftriaxone is used commonly in People’s Republic of China. The CTX-M type of ESBLKP that decomposes antibacterial drugs is different from the SHV type and TEM type, and there are also differences in antibiotic selection for treatment. It is necessary to strengthen the research on the origin, transmission, and treatment of CTX-M ESBL in People’s Republic of China. The increasing prevalence of ESBLKP is contributing to the increased consumption of carbapenems and leading to further increased carbapenem resistance rates in ICUs.

The China Antimicrobial Surveillance Network report in 2017 showed that the resistance rate of CRKP had increased rapidly from 6.4% in 2014 to 9.0% in 2017. The highest detection rate was 26.9% in some provinces. Detection rates of CRKP in the elderly, children, and adults were 10.2%, 9.1%, and 7.8%, respectively. In People’s Republic of China, the blaKPC-2 gene was prevalent among KP isolates in most parts of People’s Republic of China, while blaNDM was the major resistance gene detectable in several regions in southern China. In addition, OXA-producing KP, which are mainly found in isolated strains of children, was reported in People’s Republic of China. Detection of carbapenemase genes in CRKP strains in clinical laboratories should be improved in People’s Republic of China, which will be helpful for establishing its own epidemiological data and further research.

Above all, the KP infection and resistance rates in ICU patients are significantly increasing due to the extremely vulnerable population (reduced host defenses with deregulated immune responses), increased risk of becoming infected through multiple procedures and use of invasive devices that distort the anatomical integrity–protective barriers of patients (intubation, mechanical ventilation, vascular access, etc), prolonged hospital stays, and excessive use of broad-spectrum antimicrobial agents. In contrast to developed
countries, antibiotic overuse or misuse is still universal in People’s Republic of China, particularly in rural areas.23 People living in impoverished regions have a stronger need for antimicrobial therapy, and poverty can encourage shorter courses of treatment or use of lower-quality drugs. Next, resistance for KP is consequently emerging in the ICU settings, especially through the production of ESBLs and carbapenemases, of which the KPC, NDM, and OXA carbapenemases have emerged in recent years as the most concerning.24 ESBLs are encoded by transferable conjugative plasmids, which also often encode resistant determinants to other antibiotics.23 BlaKPC and blaOXA are transmitted by plasmids, and blaNDM is transmitted by transposons. Their potential for transfer makes effective control and treatment difficult, which has resulted in endemic and epidemic outbreaks.26 The high incidence of ESBL-producing bacteria in Chinese communities is partly caused by the high incidence of these bacteria in animals. Resistant bacteria of animal origin can be transmitted to humans through the environment, food products, or direct contact with livestock.27 Furthermore, due to the large populations in general hospitals, it is difficult to implement hospital infection management measures effectively, including implementation of multimodal infection prevention and control strategies, hand hygiene compliance for the control of CRE, contact precautions, patient isolation, environmental cleaning, and surveillance cultures of the environment for MDRKP.28 The prevention and control of multidrug-resistant hospital infections need to be strengthened, improving the level of prevention and control of multidrug-resistant infections in People’s Republic of China.

We acknowledge several limitations to this study. First, our analysis was retrospective, and it is possible that there may have been some degree of misclassification of the source of infection. Second, we do not distinguish between health care-associated infections and community-acquired infections. The likelihood that the isolated organism is a colonizing bacterium may be considered in such studies. We minimized this possibility through the inclusion criterion that a patient had to have a suspected infection; therefore, certain observations may not be applicable to other settings.

Conclusion
In summary, CRKP and ESBLKP prevalence and resistance rates have gradually increased in ICUs in the past 5 years. The reasons driving the high ESBL rate and increase in CREKP are various. Regular surveillance of resistance patterns in each country, or each hospital, is warranted to establish its own epidemiological data such as the molecular typing of isolates. Finally, further implementation of infection control policies, including appropriate use of antibiotics based on drug sensitivity tests, slowing down the production of multidrug-resistant bacteria, and preventing the spread of drug-resistant bacteria, would be effective in decreasing the damage of antibiotic-resistant bacteria. Prevention and control of drug-resistant bacteria is not insurmountable, but will require a shift in behavior and attitudes among senior managers and, ultimately, all health care workers providing patient care.

Acknowledgments
This work was supported in part by the Natural Science Foundation of Chongqing (Grant No. CSTC2009bb5061) and the National Personnel Research Fund (Grant No.09958013). The authors are grateful to Prof Zhe Yuan (First Affiliated Hospital, Chongqing Medical University, People’s Republic of China).

Author contributions
All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Won SY, Munoz-Price LS, Lolans K, et al. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis. 2011;53(6):532–540.
2. Galán JC, González-Candelas F, Rolain JM, Cantón R. Antibiotics as selectors and accelerators of diversity in the mechanisms of resistance: from the resistome to genetic plasticity in the β-lactamases world. Front Microbiol. 2013;4:9.
3. Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA. 2008;300(24):2911–2913.
4. Hu Y, Ping Y, Li L, Xu H, Yan X, Dai H. A retrospective study of risk factors for carbapenem-resistant Klebsiella pneumoniae acquisition among ICU patients. J Infect Dev Ctries. 2016;10(3):208–213.
5. Wang Z, Qin RR, Huang L, Sun LY. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection and mortality of Klebsiella pneumoniae infection. Chin Med J (Engl). 2018;131(1):56–62.
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-fourth informational supplement. CLSI document, approved standard M100–S24. Wayne (PA): The Institute; 2014.
7. Yan J, Pu S, Jia X, et al. Multidrug resistance mechanisms of carbapenem resistant Klebsiella pneumoniae strains isolated in Chongqing, China. Ann Lab Med. 2017;37(5):398–407.
8. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
9. O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. The Hospital Infection Control Practices Advisory Committee, Center for Disease Control and Prevention, U.S. Pediatrics. 2002;110(5):e51.

10. Clark NM, Patterson J, Lynch JP. Antimicrobial resistance among Gram-negative organisms in the intensive care unit. Curr Opin Crit Care. 2003;9(5):413–423.

11. Pitout JD. Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 2010;70:313–333.

12. Zhou H, Li G, Chen B, et al. Expert consensus on coping strategies of bacterial infection in Chinese extended-spectrum β-lactamase. Chin J Med. 2014;94(24):1847–1856.

13. Hu FP, Guo Y, Zhu DM, et al. Resistance trends among clinical isolates of extended-spectrum β-lactamase in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect. 2016;22(Suppl 1):S9–S14.

14. Yunsong Y. Prevalence of extended-spectrum β-lactamase and its antibacterial agents in clinical isolates from China. Chin J Med. 2004;84(22):1918–1920.

15. Ji S, Gu Y, Tan W, et al. Study on the genotype of extended-spectrum β-lactamase of Escherichia coli and Klebsiella pneumoniae in some parts of China. J Clin Lab Med. 2004;27(9):590–593.

16. Fupin HU, Yan G, Demei Z. Monitoring of CHINET bacterial resistance in China in 2017. Chin J Infect Chemother. 2018;18(3):241–251.

17. Annual report of Taiwan nosocomial infection surveillance systems; 2011. Available from: http://www.kmuht.org.tw/info/admin/actboard/data/20125112222508.pdf. Accessed April 6, 2013.

18. Nordmann P, Dortet L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18(5):263–272.

19. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9(4):228–236.

20. Zhang R, Liu L, Zhou H, et al. Nationwide surveillance of clinical carbapenem-resistant Enterobacteriaceae (CRE) strains in China. EBioMedicine. 2017;19:98–106.

21. Yin D, Dong D, Li K, et al. Clonal dissemination of OXA-232 carbapenemase-producing Klebsiella pneumoniae in neonates. Antimicrob Agents Chemother. 2017;61(8):e00385–17.

22. Kahlen R, Moreno R, Ranieri VM, Rhodes A, editors. 25 Years of Progress and Innovation in Intensive Care Medicine. Berlin, Germany: Medizinisch issenschaftliche Verlagsgesellschaft; 2007:199–211.

23. Xiao Y, Zhang J, Zheng B, Zhao L, Li S, Li L. Changes in Chinese policies to promote the rational use of antibiotics. PLoS Med. 2013;10(11):e1001556.

24. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care. 2011;1(1):47.

25. Ali Abdel Rahim KA, Ali Mohamed AM. Prevalence of extended spectrum β-lactamase-producing Klebsiella pneumoniae isolates. Jundishapur J Microbiol. 2014;7(11):e17114.

26. Zhihong Y, Zhenzhen L. Advances in epidemiology, drug resistance and transmission mechanism of carbapenem-resistant Klebsiella pneumoniae. Chin J Antidiab. 2017;12:1107–1112.

27. Quan J, Zhao D, Liu L, et al. High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections in China. J Antimicrob Chemother. 2017;72(1):273–280.

28. Tomczyk S, Zanichelli V, Grayson ML, et al. Control of Carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in healthcare facilities: a systematic review and reanalysis of quasi-experimental studies. Clin Infect Dis. Epub 2018 Nov 23.